RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cellsCharlotte Pilard, Michaël Herfs|Journal for ImmunoTherapy of Cancer|2025Cited by 7